Alto Neuroscience Q1 FY26 net loss widens to $26.24 million; R&D expense climbs to $20.29 million

Alto Neuroscience

Alto Neuroscience

ANRO

0.00
  • Alto Neuroscience posted a net loss of USD 26.24 million, widening from USD 15.17 million a year earlier.
  • Research and development expense more than doubled to USD 20.29 million, while general and administrative costs rose to USD 6.84 million.
  • Operating loss widened to USD 27.14 million as total operating expenses climbed to USD 27.14 million.
  • Cash, cash equivalents and restricted cash totaled USD 264.3 million at March 31, 2026, up from USD 177 million at Dec. 31, 2025.
  • Initiated Phase 2b trial of ALTO-207 in April 2026 with topline data expected in second half of 2027, while ALTO-300 Phase 2b topline data is expected in first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001999480-26-000012), on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.